BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 22707137)

  • 1. Impact of detectable human cytomegalovirus DNAemia on viro-immunological effectiveness of HAART in HIV-infected patients naive to antiretroviral therapy.
    Focà E; Motta D; Pollara C; Brianese N; Gotti D; Albini L; Quiros-Roldan E; Torti C; Manca N
    New Microbiol; 2012 Apr; 35(2):227-31. PubMed ID: 22707137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human cytomegalovirus (HCMV)-specific CD4+ T lymphocyte response in AIDS patients with no past or current HCMV disease following HAART.
    Tamarit A; Alberola J; Mir A; Benet I; Mira JV; Muñoz C; Galindo MJ; Navarro D
    J Clin Virol; 2004 Apr; 29(4):308-14. PubMed ID: 15018860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent CMV and EBV DNAemia is significantly correlated with a delay in the response to HAART in treatment-naive HIV type 1-positive patients.
    Panagiotakis SH; Soufla G; Baritaki S; Sourvinos G; Passam A; Zagoreos I; Stavrianeas N; Spandidos DA
    AIDS Res Hum Retroviruses; 2007 Jan; 23(1):10-8. PubMed ID: 17263627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of human cytomegalovirus (HCMV)-specific CD4+ T cell frequency by cytokine flow cytometry as a possible indicator for discontinuation of HCMV secondary prophylaxis in HAART-treated AIDS patients.
    Lilleri D; Piccinini G; Genini E; Comolli G; Chiesa A; Tordato F; Sotgiu G; Parisi A; Baldanti F; Revello MG; Gerna G
    J Clin Virol; 2004 Apr; 29(4):297-307. PubMed ID: 15018859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of highly active antiretroviral therapy on cytomegalovirus viraemia in the absence of specific anti-cytomegalovirus therapy.
    Mihăilescu R; Arama V; Paraschiv S; Streinu-Cercel A; Oţelea D; Munteanu D; Iosipenco M; Chiotan C; Benea OE; Mărdărescu M; Rădulescu M; Hristea A; Ungurianu R; Aramă SS; Cercel AS; Călin R; Băicuş C
    Rom J Intern Med; 2008; 46(4):305-11. PubMed ID: 19480296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sharp drop in the prevalence of human cytomegalovirus leuko-DNAemia in HIV-infected patients following highly active antiretroviral therapy.
    Gerna G; d'Arminio Monforte A; Zavattoni M; Sarasini A; Testa L; Revello MG; Moroni M
    AIDS; 1998 Jan; 12(1):118-20. PubMed ID: 9456267
    [No Abstract]   [Full Text] [Related]  

  • 7. Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAART.
    Gerna G; Piccinini G; Genini E; Percivalle E; Zavattoni M; Lilleri D; Testa L; Comolli G; Maserati R; Baldanti F; Maccario R; Monforte AD; Revello MG
    J Acquir Immune Defic Syndr; 2001 Dec; 28(4):320-31. PubMed ID: 11707667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy.
    Keane NM; Price P; Lee S; Almeida CA; Stone SF; James I; French MA
    HIV Med; 2004 Nov; 5(6):407-14. PubMed ID: 15544692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CMV DNA levels and CMV gB subtypes in ART-naive HAART-treated patients: a 2-year follow-up study in The Netherlands.
    Goossens VJ; Wolffs PF; van Loo IH; Bruggeman CA; Verbon A
    AIDS; 2009 Jul; 23(11):1425-9. PubMed ID: 19531930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis.
    Komanduri KV; Feinberg J; Hutchins RK; Frame RD; Schmidt DK; Viswanathan MN; Lalezari JP; McCune JM
    J Infect Dis; 2001 Apr; 183(8):1285-9. PubMed ID: 11262214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
    Salmon-Céron D; Mazeron MC; Chaput S; Boukli N; Senechal B; Houhou N; Katlama C; Matheron S; Fillet AM; Gozlan J; Leport C; Jeantils V; Freymuth F; Costagliola D
    AIDS; 2000 May; 14(8):1041-9. PubMed ID: 10853987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of human cytomegalovirus infection in patients infected with human immunodeficiency virus by high levels of specific CD8+ T-cells.
    Lilleri D; Chiesa A; Fornara C; Maserati R; Lozza L; Comolli G; Gerna G
    Clin Microbiol Infect; 2007 Jan; 13(1):19-24. PubMed ID: 17184283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of human cytomegalovirus-specific CD4(+) T-cell frequency and lymphoproliferative response in human immunodeficiency virus-positive patients.
    Piccinini G; Comolli G; Genini E; Lilleri D; Gulminetti R; Maccario R; Revello MG; Gerna G
    Clin Diagn Lab Immunol; 2001 Nov; 8(6):1225-30. PubMed ID: 11687467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of human cytomegalovirus specific T cell immunity in human immunodeficiency virus infected patients in different disease stages following HAART and in long-term non-progressors.
    Tamarit A; Alberola J; Mira JV; Tornero C; Galindo MJ; Navarro D
    J Med Virol; 2004 Nov; 74(3):382-9. PubMed ID: 15368523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy.
    O'Sullivan CE; Drew WL; McMullen DJ; Miner R; Lee JY; Kaslow RA; Lazar JG; Saag MS
    J Infect Dis; 1999 Sep; 180(3):847-9. PubMed ID: 10438377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition.
    Cingolani A; Cozzi Lepri A; Castagna A; Goletti D; De Luca A; Scarpellini P; Fanti I; Antinori A; d'Arminio Monforte A; Girardi E
    Clin Infect Dis; 2012 Mar; 54(6):853-61. PubMed ID: 22157323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy.
    Deayton JR; Prof Sabin CA; Johnson MA; Emery VC; Wilson P; Griffiths PD
    Lancet; 2004 Jun; 363(9427):2116-21. PubMed ID: 15220032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of reactivation of cytomegalovirus retinitis in patients healed after treatment with highly active antiretroviral therapy.
    Song MK; Karavellas MP; MacDonald JC; Plummer DJ; Freeman WR
    Retina; 2000; 20(2):151-5. PubMed ID: 10783947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.